Akari Therapeutics (NASDAQ:AKTX) Share Price Passes Below 200 Day Moving Average – Should You Sell?

Akari Therapeutics, Plc (NASDAQ:AKTX)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.35 and traded as low as $1.10. Akari Therapeutics shares last traded at $1.14, with a volume of 47,706 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Akari Therapeutics in a research report on Thursday. They issued a “sell” rating for the company.

Akari Therapeutics Trading Down 2.6 %

The stock’s fifty day moving average price is $1.17 and its 200-day moving average price is $2.35.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.